10-K/A: Y-mAbs Therapeutics Files Amendment to 10-K, Updates Director Compensation Policy
Form 10-K/A Amendment
Y-mAbs Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update the exhibit list, while also revising its non-employee director compensation policy.
Summary
- Y-mAbs Therapeutics, Inc. filed Amendment No. 1 on Form 10-K/A to its Annual Report for the year ended December 31, 2024.
- The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which was previously omitted.
- Item 15 of Part IV of the Original 10-K was updated to revise the exhibit list.
- The filing includes currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- The document details the compensation of directors and executive officers, including base salaries, bonus opportunities, and equity incentives.
- The company's non-employee director compensation policy was amended and restated, effective March 18, 2025, adjusting the annual equity award component.
- The amendment also provides information on security ownership, related person transactions, and principal accountant fees and services.
Sentiment
Score: 7
Explanation: The document is a regulatory filing, so the sentiment is neutral. However, the inclusion of detailed compensation information and corporate governance practices suggests a commitment to transparency, which is viewed positively.
Positives
- The company has a clawback policy in place to recover erroneously awarded compensation.
- The company's compensation committee actively engages with stockholders to gather feedback on executive compensation and corporate governance issues.
- The company offers health insurance and a 401(k) retirement plan to its U.S. employees.
- The company has an equity granting policy to ensure fair and consistent equity awards to employees and directors.
- The company maintains a general liability insurance policy covering directors and officers.
Future Outlook
The Compensation Committee will continue to monitor the outcome of the advisory vote on named executive officer compensation at the Annual Meeting and will consider the voting results in future executive compensation decisions.
Industry Context
The document references peer groups in the biotechnology sector to benchmark executive and director compensation, indicating an awareness of industry standards and competitive practices.
Comparison to Industry Standards
- The Compensation Committee targets the 50th percentile of the peer group for base salary and target total cash.
- The Compensation Committee targets between the 50th and 75th percentile for long-term equity incentives for executive officers.
- The peer group consists of companies like Aadi Bioscience, Agios Pharmaceuticals, Arcus Biosciences, and others in the biotechnology sector with similar market capitalization, revenue, and employee size.
- Aon provides compensation data related to executives at the peer group based on data from SEC filings and the Aon Global Life Sciences Survey.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Non-Employee Director Compensation Policy | Adjusted the annual equity award component, setting the aggregate grant date fair value for both non-qualified stock options and restricted stock units at $122,000. | March 18, 2025 | Aims to align the equity component of non-employee director compensation to the 50th percentile of the peer group. |
Stakeholder Impact
- Shareholders: The document provides transparency regarding executive and director compensation, which can influence investor confidence.
- Employees: The document outlines compensation policies and benefits, which can impact employee morale and retention.
- Directors: The document details the compensation and responsibilities of directors, which can influence their decision-making and commitment to the company.
Next Steps
- The Compensation Committee will continue to evaluate the compensation program and review stockholder feedback going forward.
- The company will continue to monitor the outcome of the advisory vote on named executive officer compensation at the Annual Meeting and will consider the voting results in future executive compensation decisions.
Key Dates
| Date | Description |
|---|---|
| August 20, 2015 | Date of original License Agreement with Memorial Sloan Kettering Cancer Center |
| April 1, 2016 | Effective date of Service Agreement between Y-mAbs and Thomas Gad |
| October 1, 2016 | Effective date of Service Agreement between Y-mAbs Therapeutics A/S and Bo Kruse |
| August 1, 2017 | Effective date of Employment Agreement for Dr. Steen Lisby |
| November 13, 2017 | Date of Sponsored Research Agreement between Y-mAbs and Memorial Sloan Kettering Cancer Center |
| January 10, 2018 | Date of Lease Agreement between Y-mAbs and RXR HB Owner LLC |
| April 15, 2020 | Effective date of License Agreement among Y-mAbs, Memorial Sloan Kettering Cancer Center, and Massachusetts Institute of Technology |
| June 1, 2020 | Effective date of Amendment to Employment Agreement for Dr. Steen Lisby |
| October 7, 2020 | Effective date of Master Sponsored Research Agreement between Y-mAbs and Memorial Sloan Kettering Cancer Center |
| December 17, 2020 | Date of License Agreement between Y-mAbs and SciClone Pharmaceuticals International Ltd. |
| March 18, 2021 | Date of Amendment No. 1 to License Agreement between Y-mAbs and Memorial Sloan Kettering Cancer Center |
| September 28, 2022 | Board of Directors resolved to change the vesting terms for stock options going forward |
| October 17, 2023 | Date of Employment Agreement between Y-mAbs and Michael Rossi |
| August 16, 2023 | Date of Amendment to Lease Agreement between Y-mAbs and RXR HB Owner LLC |
| March 21, 2024 | Date of Severance Agreement between Y-mAbs Therapeutics A/S and Steen Lisby |
| April 26, 2024 | Effective date of Amended and Restated Non-Employee Director Compensation Policy |
| June 28, 2024 | Date of Employment Agreement between Y-mAbs and Peter Pfreundschuh |
| July 16, 2024 | Date of Separation Agreement between Bo Kruse and Y-mAbs Therapeutics A/S and Consultancy Agreement between Y-mAbs and Investeringsselskabet GH ApS |
| September 11, 2024 | Date of Lease Agreement and License Agreement between Y-mAbs and Princeton 202 Associates Limited Partnership |
| October 29, 2024 | Date of License Agreement between Y-mAbs and Nobelpharma, Co., Ltd. |
| December 9, 2024 | Effective date of Amendment No.1 to License Agreement between Y-mAbs and SciClone Pharmaceuticals International Ltd |
| March 18, 2025 | Effective date of Amended and Restated Non-Employee Director Compensation Policy |
| April 14, 2025 | Date used for security ownership calculations |
| April 28, 2025 | Date of report signature |
Keywords
executive compensation, director compensation, corporate governance, equity incentives, Form 10-K/A, Y-mAbs Therapeutics, Sarbanes-Oxley Act, proxy statement, stock options, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.